TY - JOUR
AU - S. Shapiro
AU - H. Yin
AU - O. H. Y. Yu
AU - L. Azoulay
AD - Centre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital, 3755 Cote Sainte-Catherine, H425.1, Montreal, H3T 1E2, Canada.
Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, H3A 1G1, Canada.
Division of Endocrinology, Jewish General Hospital, Montreal, H3T 1E2, Canada.
Centre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital, 3755 Cote Sainte-Catherine, H425.1, Montreal, H3T 1E2, Canada. laurent.azoulay@mcgill.ca.
Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, H3A 1G1, Canada. laurent.azoulay@mcgill.ca.
Gerald Bronfman Department of Oncology, McGill University, Montreal, H4A 3T2, Canada. laurent.azoulay@mcgill.ca.
AN - 38720114
BT - Drug Saf
DO - 10.1007/s40264-024-01434-4
DP - NLM
ET - 2024/05/09
LA - eng
N1 - 1179-1942
Shapiro, Samantha B
Orcid: 0000-0002-7957-508x
Yin, Hui
Yu, Oriana H Y
Azoulay, Laurent
Orcid: 0000-0001-5162-3556
FDN-143328/CAPMC/CIHR/Canada
Journal Article
New Zealand
Drug Saf. 2024 May 8. doi: 10.1007/s40264-024-01434-4.
PY - 2024
SN - 0114-5916
T2 - Drug Saf
TI - Dipeptidyl Peptidase-4 Inhibitors and the Risk of Gallbladder and Bile Duct Disease Among Patients with Type 2 Diabetes: A Population-Based Cohort Study
ER -